KM Research Hub
← 返回论文库
无 KM 图 入排:排除 图源:可得 入排置信度 0.98

Tenecteplase versus standard care in patients with acute basilar artery occlusion: a multi-centre, prospective, randomised, open-label, blinded endpoint, phase 3, controlled trial.

Yunyun Xiong, Fana Alemseged, Zhixin Cao, Lee H Schwamm, Mark Parsons, Marc Fisher, Shuangzhe Wu, Bruce C V Campbell, Yongjun Wang

Stroke Vasc Neurol 11(3) 365-372

PMID41151803
PMCIDPMC13347805
DOI10.1136/svn-2025-004432
发表日期2025-10-28
入排依据:未发现恶性肿瘤人群证据。
疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 已检查 4 张 PMC Figure,均未识别为 KM 图:Figure 1:非 KM 图;Figure 2:非 KM 图;Figure 3:非 KM 图;Figure 4:非 KM 图。
摘要

摘要

BACKGROUND AND PURPOSE: There is a scarcity of evidence of tenecteplase administered within the 24-hour window of acute ischaemic stroke due to basilar artery occlusion (BAO). We sought to assess whether intravenous tenecteplase within 24 hours of stroke onset, with or without endovascular treatment (EVT), leads to superior outcomes compared with standard care in acute BAO. METHODS AND DESIGN: Tenecteplase Reperfusion therapy in Acute ischaemic Cerebrovascular Events-5 (TRACE-5), using a prospective, randomised, open-label, blinded-endpoint design, will enrol patients with acute ischaemic stroke due to BAO within 24 hours of the time they were last known well. Patients will be randomised to either intravenous tenecteplase (0.25 mg/kg, maximum 25 mg) or standard care. EVT is allowed in both groups. STUDY OUTCOMES: Modified Rankin Scale (mRS) of 0-1 or return to baseline mRS at 90 days is the primary outcome. Secondary outcomes include mRS 0-2 or return to baseline, mRS 0-3 and mRS distribution at 90 days, early neurological improvement within 72 hours and substantial reperfusion at initial angiogram. Safety outcomes are symptomatic intracranial haemorrhage within 36 hours, death within 90 days and mRS 5-6 at 90 days. DISCUSSION: The TRACE-5 trial will address whether extended-time window thrombolysis with a potentially more effective thrombolytic agent tenecteplase±EVT is superior to standard care in BAO. TRIAL REGISTRATION NUMBER: NCT06196320.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。
其他 Figure(4,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

Figure 1Detailed inclusion and exclusion criteria.
非 KM Figure
Figure 2Study flow chart. BAO, basilar artery occlusion; CTA, CT angiography; MRA, MR angiography; mRS, modified Rankin Scale.
非 KM Figure
Figure 3Trial assessment flow chart. Treatment=intravenous thrombolysis with tenecteplase 0.25 mg/kg then patients receive endovascular thrombectomy if required. These are standard care clinical tests performed as part of routine patient care—the first set of results for the admission will be collected, when available. Day 90 visit performed centrally by the regional coordinating centre over the phone or in person. Imaging examinations will also be performed when clinical symptoms worsen. In the case of unscheduled visits for adverse events, results of routine CT and NIHSS assessments will be collected. Adverse event data will not be collected unless for mortality. INR, International normalised ratio; mRS, modified Rankin Scale; NIHSS, National Institutes of Health Stroke Scale; sICH, symptomatic intracranial haemorrhage; PT, prothrombin time.
非 KM Figure
Figure 4Efficacy and safety outcomes. eTICI, expanded Thrombolysis In Cerebral Infarction; mRS, modified Rankin Scale; NIHSS, National Institutes of Health Stroke Scale; PH, parenchymal haematoma; sICH, symptomatic intracranial haemorrhage.
非 KM Figure